Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleni Efstathiou

Showing results (51-60 of 150) with videos related to

Pageof 15
Sort By:
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myelomaMeletios A Dimopoulos, George Hamilos, Athanasios Zomas, et al.
Urologic Oncology|January 19, 2016
First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registryJean-Pierre Droz, Eleni Efstathiou, Asif Yildirim, et al.
Clinical Genitourinary Cancer|November 22, 2024
The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study: Cabazitaxel in mCRPC patients with osseous metastasesMichalis Liontos, Anna Goussia, Nikolaos Korfiatis, et al.
European Urology|October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer MonitoringFred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatmentVassiliki Tzelepi, Eleni Efstathiou, Sijin Wen, et al.
European Urology|June 3, 2014
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancerEleni Efstathiou, Mark Titus, Sijin Wen, et al.
Gynecologic Oncology|May 3, 2005
Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experienceDimitrios Pectasides, George Fountzilas, Gerasimos Aravantinos, et al.
Gynecologic Oncology|December 8, 2004
Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter studyMeletios A Dimopoulos, Christos Papadimitriou, Georgios Hamilos, et al.
BMC Cancer|September 27, 2006
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology GroupAristotle Bamias, Christos Papadimitriou, Eleni Efstathiou, et al.
Oncology|August 11, 2006
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experienceGeorge Bozas, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Pageof 15

Showing results (51-60 of 150) with videos related to

Sort By:
Pageof 15
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myelomaMeletios A Dimopoulos, George Hamilos, Athanasios Zomas, et al.
Urologic Oncology|January 19, 2016
First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registryJean-Pierre Droz, Eleni Efstathiou, Asif Yildirim, et al.
Clinical Genitourinary Cancer|November 22, 2024
The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study: Cabazitaxel in mCRPC patients with osseous metastasesMichalis Liontos, Anna Goussia, Nikolaos Korfiatis, et al.
European Urology|October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer MonitoringFred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatmentVassiliki Tzelepi, Eleni Efstathiou, Sijin Wen, et al.
European Urology|June 3, 2014
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancerEleni Efstathiou, Mark Titus, Sijin Wen, et al.
Gynecologic Oncology|May 3, 2005
Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experienceDimitrios Pectasides, George Fountzilas, Gerasimos Aravantinos, et al.
Gynecologic Oncology|December 8, 2004
Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter studyMeletios A Dimopoulos, Christos Papadimitriou, Georgios Hamilos, et al.
BMC Cancer|September 27, 2006
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology GroupAristotle Bamias, Christos Papadimitriou, Eleni Efstathiou, et al.
Oncology|August 11, 2006
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experienceGeorge Bozas, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Pageof 15